Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas W Weiss

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Human Vaccines & Immunotherapeutics|April 3, 2024
Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United StatesSalini Mohanty, Jui-Hua Tsai, Ning Ning, et al.
Wiener Klinische Wochenschrift|September 15, 2016
Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experienceMiklos Rohla, Ioannis Tentzeris, Matthias K Freynhofer, et al.
Frontiers in Cardiovascular Medicine|March 29, 2022
Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary InterventionMaximilian Tscharre, Serdar Farhan, Matthias K Freynhofer, et al.
The American Journal of Managed Care|July 11, 2009
Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trialAimee Der-Huey Shu, Margaret R Stedman, Jennifer M Polinski, et al.
Metabolism: Clinical and Experimental|March 18, 2014
Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levelsAnna Wonnerth, Katharina M Katsaros, Konstantin A Krychtiuk, et al.
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Plos One|June 21, 2017
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registryMaximilian Tscharre, Florian Egger, Matthias Machata, et al.
Heart Rhythm|July 19, 2014
High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantationFlorian Egger, Michael Nürnberg, Miklos Rohla, et al.
International Journal of Cardiology|July 9, 2016
Endpoint design for future renal denervation trials - Novel implications for a new definition of treatment response to renal denervationThomas Lambert, Alexander Nahler, Miklos Rohla, et al.
Thrombosis and Haemostasis|March 18, 2006
The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathwaySvitlana Demyanets, Stefan Pfaffenberger, Christoph Kaun, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Human Vaccines & Immunotherapeutics|April 3, 2024
Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United StatesSalini Mohanty, Jui-Hua Tsai, Ning Ning, et al.
Wiener Klinische Wochenschrift|September 15, 2016
Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experienceMiklos Rohla, Ioannis Tentzeris, Matthias K Freynhofer, et al.
Frontiers in Cardiovascular Medicine|March 29, 2022
Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary InterventionMaximilian Tscharre, Serdar Farhan, Matthias K Freynhofer, et al.
The American Journal of Managed Care|July 11, 2009
Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trialAimee Der-Huey Shu, Margaret R Stedman, Jennifer M Polinski, et al.
Metabolism: Clinical and Experimental|March 18, 2014
Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levelsAnna Wonnerth, Katharina M Katsaros, Konstantin A Krychtiuk, et al.
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Plos One|June 21, 2017
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registryMaximilian Tscharre, Florian Egger, Matthias Machata, et al.
Heart Rhythm|July 19, 2014
High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantationFlorian Egger, Michael Nürnberg, Miklos Rohla, et al.
International Journal of Cardiology|July 9, 2016
Endpoint design for future renal denervation trials - Novel implications for a new definition of treatment response to renal denervationThomas Lambert, Alexander Nahler, Miklos Rohla, et al.
Thrombosis and Haemostasis|March 18, 2006
The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathwaySvitlana Demyanets, Stefan Pfaffenberger, Christoph Kaun, et al.
Pageof 10